Trial Profile

A dose confirmation study of SY-2101 in patients with newly diagnosed APL

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 12 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Arsenic trioxide (Primary) ; Arsenic trioxide
Indications Acute promyelocytic leukaemia
Focus Adverse reactions; Pharmacokinetics
Sponsors Syros Pharmaceuticals

Most Recent Events

09 Jan 2023 According to a Syros Pharmaceuticals media release, the company plans to provide an update on this study as well as the development path and timing for further evaluation of SY-2101 in a registration enabling study in APL, in the second half of 2023.
10 Jan 2022 According to a Syros Pharmaceuticals media release, PK and safety data expected in mid 2022.
29 Sep 2021 According to a Syros media release, the first patient has been dosed in the study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com